

Contents

Chapter 1	What is the purpose of this book?	1
Chapter 2	Why is benefit-to-harm balance essential to treatment decisions?	5
Chapter 3	What are the strengths of randomized controlled clinical trials?	11
Chapter 4	What are the weaknesses of randomized controlled clinical trials?	17
Chapter 5	Do meta-analyses provide the ultimate truth?	23
Chapter 6	What are the strengths of observational studies?	29
Chapter 7	What are the weaknesses of observational studies?	35
Chapter 8	Were the scientific questions specified in advance?	39
Chapter 9	Were the treatment groups comparable initially?	45
Chapter 10	Why is blinding/masking so important?	49
Chapter 11	How is symptomatic improvement measured?	53
Chapter 12	Is it really possible to assess quality of life?	57
Chapter 13	What is the value of biologic markers in drug evaluation?	61
Chapter 14	How are adverse drug reactions measured?	67
Chapter 15	How representative are study subjects in clinical trials?	73
Chapter 16	What happened to the study subjects who disappeared from the analysis?	77
Chapter 17	How reliable are active-control trials?	83
Chapter 18	How informative are composite outcomes?	89
Chapter 19	Do changes in biologic markers predict clinical benefit?	95
Chapter 20	How trustworthy are the authors?	99
Chapter 21	Does publication in a reputable scientific journal guarantee quality?	103
Chapter 22	Is it necessary to be a biostatistician to interpret scientific data?	107
Chapter 23	Are all drugs of a class interchangeable?	115
Chapter 24	How much confidence can be placed on economic analysis?	121
Chapter 25	How should I handle the massive flow of information?	125
Chapter 26	How well is research translated into clinical care?	131
Appendix A	Glossary	137
Appendix B	Explanations for checklist questions	143
References		149
Index		159
About the Authors		163

Evaluating Clinical Research

All that glitters is not gold

Furberg, B.D.; Furberg, C.D.

2007, V, 165 p., Softcover

ISBN: 978-0-387-72898-8